Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

203/212Pb PSV359 - Perspective Therapeutics

Next Previous
Drug Profile

203/212Pb PSV359 - Perspective Therapeutics

Alternative Names: [212Pb]Pb-PSV359 - Perspective Therapeutics; Lead-212 PSV359 - Perspective Therapeutics; PSV359 - Perspective Therapeutics

Latest Information Update: 27 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Perspective Therapeutics
  • Class Antineoplastics; Imaging agents; Lead radioisotopes; Peptides; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 02 Jun 2026 Efficacy and adverse events data from a phase I/IIa trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 28 Apr 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) (NCT06710756)
  • 23 Oct 2024 Pharmacokinetics data from a preclinical trial in Solid tumours released by Perspective Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top